Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in Japan for Tr ...
PDF (174 KB)
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric ...
PDF (179 KB)
Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual Meeting
PDF (230 KB)
Daiichi Sankyo to Present New Preclinical and Translational Research from DXd ADC Portfolio at AACR ...
PDF (198 KB)
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small ...
PDF (179 KB)
ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer
PDF (186 KB)
Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Can ...
PDF (139 KB)
Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastati ...
PDF (256 KB)
Daiichi Sankyo and Syneos Health® Form Strategic Coalition for Development of Daiichi Sankyo’s ADC ...
PDF (231 KB)
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KE ...
PDF (189 KB)
Showing 1 - 10 of 44 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...